Oxford BioDynamics Plc (OBD) · 2026-08-27

Board Appointment

Oxford BioDynamics has appointed Chief Executive Officer Richard Compton to its Board as an Executive Director with immediate effect.

Oxford BioDynamics Plc (OBD) · 2026-08-13

Partnership with Dubai London Clinics & Hospitals

Oxford BioDynamics has partnered with Dubai London Clinics & Hospitals to offer EpiSwitch PSE across five UAE facilities, its first Gulf commercial partnership.

Oxford BioDynamics Plc (OBD) · 2026-07-28

First commercial agreement for EpiSwitch® Orion

Oxford BioDynamics has secured its first paid third-party agreement for EpiSwitch Orion, covering biomarker discovery, genomic sequence processing and insight generation under the OPTIMISE research programme.

Oxford BioDynamics Plc (OBD) · 2026-06-30

Interim Results

Oxford BioDynamics said H1 trading was in line with management expectations, with revenue up to £0.69m from £0.59m and operating loss narrowing to £4.68m. Cash and term deposits were £2.51m at 31 March 2026, but cash fell to £1.38m at 31 May and the group expects to need additional funds by late August 2026.

Oxford BioDynamics Plc (OBD) · 2026-06-30

US contract sales partnership

Oxford BioDynamics has signed a commercial services agreement with MK Commercial Group to initially deploy seven field-based sales professionals across the US for EpiSwitch PSE, with capacity to scale to 35 representatives.

Oxford BioDynamics Plc (OBD) · 2026-06-30

Appointment of Chief Executive Officer

Oxford BioDynamics has appointed Richard Compton as Chief Executive Officer with immediate effect. He is expected to join the Group's Board in due course, subject to normal regulatory due diligence by the Company's Nomad.